Treatment
renal impairment
RENAL IMPAIRMENT
The treatment period was 12 weeks. Mirogabalin was administered orally at 5 mg twice daily during the first week of the titration period and was titrated up to 10–15 mg twice daily in the following weeks based on age, symptoms, and renal function. For patients with moderate renal impairment (i.e. creatinine clearance 30 to < 60 mL/min), the maintenance dose was 5–7.5 mg twice daily according to the package insert [Prohibited medications included pregabalin, gabapentin, carbamazepine, duloxetine, and lorazepam. The use of compression therapy, cryotherapy, or acupuncture was also prohibited. Co-administration of opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and acetaminophen was permitted if they were administered prior to enrollment and no changes in dosage or administration were made during the study period.